People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

WeightWatchers has plans to file for bankruptcy in the coming months, a source familiar with the matter said on Wednesday.

WeightWatchers faces bankruptcy with £1.25 billion ($1.6 billion) in debt, losing clients to drugs like Ozempic. Can the ...

AI fundraises, tech partnerships and M&A deals, including DispatchHealth and Medically Home's tie-up, and plans for a ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Key Takeaways Hims & Hers is now offering Zepbound and generic liraglutide for weight lossZepbound is priced at ...

U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Wednesday. The company also said it sees first-quarter total revenues of $138.75 million to $140.75 ...

The FDA's new rule restricting the sale of compounded semaglutide could make it more difficult for some people to obtain affordable weight loss medications. Here, two people who've relied on ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Joelle Pineau said she would step down effective May 30, creating an executive vacancy as the company aggressively invests and competes in the booming sector. Visa, Amex and Mastercard are all ...